An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

This is a randomized (the study medication is assigned by chance), double-blind (neither
physician nor participant knows the treatment that the participant receives),
placebo-controlled (an inactive substance that is compared with a medication to test whether
the medication has a real effect in a clinical study), multicenter, parallel-group (each
group of participants will be treated at the same time) study. Approximately 200
participants will be randomly assigned to JNJ 49095397 or placebo in the ratio 1:1. The
study consists of 3 phases: screening (3 weeks), double-blind treatment (12 weeks), and
follow up (4 weeks). Safety evaluations will include assessment of adverse events, vital
signs, physical examination, electrocardiograms, and clinical laboratory tests which will be
monitored throughout the study. The total duration of the study for each participant will be
approximately 19 weeks.

Inclusion Criteria:

- Men and women of non-child-bearing potential, Global Initiative for Chronic
Obstructive Lung Disease (GOLD 2 or 3), forced expiratory volume in one second (FEV1)
greater than or equal to 40 less than 80 percent predicted, FEV1/ forced vital
capacity (FVC) ratio less than 0.7

- Clinical history of chronic bronchitis. Either two chronic obstructive pulmonary
disease (COPD) exacerbations in past two years or ability to produce a spontaneous
sputum sample, treated with long-acting beta-2 agonist (LABA)/ long-acting muscarinic
antagonists (LAMA), with or without inhaled corticosteroids for at least 12 weeks
prior to study entry

- Smoker or ex-smoker with at least a 10 pack-year history

- No COPD exacerbation that requires change in COPD maintenance medications during the
screening period

- Not experienced a significant worsening of COPD based on clinical symptoms and by
investigations during screening period

Exclusion Criteria:

- Has another pulmonary disease (eg, asthma) or an active infection (eg, tuberculosis)

- Has experienced life-threatening COPD (eg, requiring intensive care unit [ICU]
admission, intubation, or long-term non-invasive ventilation). Short-term (less than
five days), non-invasive ventilation during a hospitalization for an acute
exacerbation of COPD is permitted, provided that non-invasive ventilation was not
continued at home

- Has right heart failure or oxygen saturation less than 90 percent at rest on room air
at screening or requires oxygen therapy on a daily basis for chronic hypoxemia
(deficiency of oxygen in blood)

- History of significant disease or medical illness within 12 months prior to screening
- Positive serology to human immunodeficiency virus (HIV)-1 or HIV-2, hepatitis B
virus, or hepatitis C virus at screening